German China

USA: New Therapies for Cancer Patients

Symphogen to Use Thermo Fisher's Mass Spectrometry Technology to Analyze Complex Therapeutic Proteins

| Editor: Alexander Stark

Symphogen will use the Thermo Scientific Q Exactive Plus Orbitrap liquid chromatography-tandem mass spectrometry (LC-MS/MS) system with Bio Pharma option.
Gallery: 1 image
Symphogen will use the Thermo Scientific Q Exactive Plus Orbitrap liquid chromatography-tandem mass spectrometry (LC-MS/MS) system with Bio Pharma option. (Source: Thermo Fisher Scientific)

Thermo Fisher Scientific and Symphogen, a clinical-stage antibody oncology-focused company, have entered into a two-year collaborative partnership to deliver validated, platform workflows for simplified characterization and quality monitoring of complex therapeutic proteins.

Sunnyvale/USA — Building on a decade-long relationship, the new collaboration will develop protein analysis workflows to accelerate drug development for biopharmaceutical innovators, biosimilar manufacturers, contract research organizations, and contract development and manufacturing organizations.

The client will use the Q Exactive Plus Orbitrap liquid chromatography-tandem mass spectrometry (LC-MS/MS) system with Bio Pharma Option to create, test and validate platform workflows for intact and native mass analysis of therapeutic monoclonal antibody (mAb) mixtures. Additional focus will be placed on the development of automated multi-attribute method (MAM) workflows for monitoring critical quality attributes of proteins using high-resolution accurate-mass mass spectrometry in a quality control environment.

LC-MS Routine Analysis for Novices and Experts

France: Mass Spectrometry

LC-MS Routine Analysis for Novices and Experts

07/10/2018 - Thermo Fisher offers a new technology for single quadrupole mass spectrometer. The system is designed for ease-of-use while offering application flexibility and reliable results for challenging mass confirmation analyses, the company says. read...

John Rontree, senior director pharma & biopharma, chromatography and mass spectrometry, Thermo Fisher Scientific, said that the growing demand for more targeted and personalized treatment modalities resulted in the development of increasingly complex drug products, requiring research and development of advanced workflows to monitor their structure, manufacturing variation and quality. The collaboration would enable the companies to jointly leverage their established mass spectrometry technology to develop and implement novel, easy-to-use analytical strategies for complex mAb mixtures needed by drug manufacturers to drive the development of new therapies for cancer patients.

Comments are being loaded ....

Leave a comment

The comment is checked by an editor and will be released soon.

  1. Avatar
    Avatar
    Edited by at
    Edited by at
    1. Avatar
      Avatar
      Edited by at
      Edited by at

Comments are being loaded ....

Report comment

Kommentar Freigeben

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

Freigabe entfernen

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

copyright

This article is protected by copyright. You want to use it for your own purpose? Infos can be found under www.mycontentfactory.de (ID: 45595580 / Laborpraxis Worldwide)